dehydrogenase/reductase 4 like 1 (pseudogene)Genealiases: []
Q-omics provides the consensus-scored DHRS4L1 profile across patient tissues and cancer cell-line models. DHRS4L1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, DHRS4L1 is differentially expressed in 8, with the highest sampling consensus in THCA. Additionally, DHRS4L1 RNA expression shows 17,362 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight BRCA, THCA, and ACC as cancer lineages where DHRS4L1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DHRS4L1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DHRS4L1 survival associations across molecular data types. DHRS4L1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DHRS4L1 RNA expression–survival associations across cancer types. High DHRS4L1 expression shows unfavorable associations in LGG, but favorable associations in BRCA, UVM, KIRC, HNSC and LUSC. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for DHRS4L1 RNA expression.
This table summarizes DHRS4L1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for DHRS4L1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DHRS4L1 shows lower tumor expression in THCA, CHOL, KIRP and BRCA and higher tumor expression in STAD and READ. The THCA box plot shows higher DHRS4L1 RNA expression in normal versus tumor tissue (log2 FC = −0.568, t-test p < 0.001).
This table shows molecular features associated with DHRS4L1 in patient tissues and cancer cell lines. In patient samples, DHRS4L1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, DHRS4L1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in BREAST.
